Detail akcie NeuroSense Rg online

Business Summary: NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Financial Summary: BRIEF: For the six months ended 30 June 2025, Neurosense Therapeutics Ltd revenues was not reported. Net loss decreased 25% to $4.7M. Lower net loss reflects Research and development expenses - Bala decrease of 40% to $1.5M (expense), Financing expenses, net decrease of 93% to $17K (expense), Stock-based Compensation in R&D decrease of 88% to $18K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.37 to -$0.19.